JP2012507988A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507988A5
JP2012507988A5 JP2011534924A JP2011534924A JP2012507988A5 JP 2012507988 A5 JP2012507988 A5 JP 2012507988A5 JP 2011534924 A JP2011534924 A JP 2011534924A JP 2011534924 A JP2011534924 A JP 2011534924A JP 2012507988 A5 JP2012507988 A5 JP 2012507988A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
seq
vegf antibody
allele
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011534924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507988A (ja
JP5701216B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/063434 external-priority patent/WO2010054110A2/en
Publication of JP2012507988A publication Critical patent/JP2012507988A/ja
Publication of JP2012507988A5 publication Critical patent/JP2012507988A5/ja
Application granted granted Critical
Publication of JP5701216B2 publication Critical patent/JP5701216B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011534924A 2008-11-05 2009-11-05 加齢黄斑変性における遺伝的多型 Expired - Fee Related JP5701216B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11166708P 2008-11-05 2008-11-05
US61/111,667 2008-11-05
US17485609P 2009-05-01 2009-05-01
US61/174,856 2009-05-01
PCT/US2009/063434 WO2010054110A2 (en) 2008-11-05 2009-11-05 Genetic polymorphisms in age-related macular degeneration

Publications (3)

Publication Number Publication Date
JP2012507988A JP2012507988A (ja) 2012-04-05
JP2012507988A5 true JP2012507988A5 (enExample) 2014-09-18
JP5701216B2 JP5701216B2 (ja) 2015-04-15

Family

ID=41650496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534924A Expired - Fee Related JP5701216B2 (ja) 2008-11-05 2009-11-05 加齢黄斑変性における遺伝的多型

Country Status (14)

Country Link
US (2) US20120003641A1 (enExample)
EP (2) EP2356250A2 (enExample)
JP (1) JP5701216B2 (enExample)
KR (1) KR101719376B1 (enExample)
CN (2) CN103333952B (enExample)
AU (1) AU2009313475B2 (enExample)
CA (1) CA2740242A1 (enExample)
DK (1) DK2540843T3 (enExample)
ES (1) ES2498274T3 (enExample)
IL (1) IL211995A (enExample)
MX (1) MX2011004763A (enExample)
PL (1) PL2540843T3 (enExample)
SI (1) SI2540843T1 (enExample)
WO (1) WO2010054110A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
RU2486253C2 (ru) 2008-07-25 2013-06-27 Инфоком Корпорейшн Онкоген nrf2 и его применение
AR085301A1 (es) * 2011-02-23 2013-09-18 Sanofi Sa Polimorfismos de un solo nucleotido en el promotor del gen vegfa y su uso como marcadores predictivos para tratamientos anti-vegf
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN110564819A (zh) 2011-05-19 2019-12-13 基纳生物技术有限公司 用于多重核酸鉴定的产品和方法
WO2013030032A1 (en) * 2011-08-26 2013-03-07 F. Hoffmann-La Roche Ag A method for predicting clinical benefit in the treatment of neurodevelopmental, neurological or neuropsychiatric disorders
MX390891B (es) * 2011-10-14 2025-03-19 Genentech Inc ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO.
US20140004105A1 (en) * 2012-06-29 2014-01-02 Sequenom, Inc. Age-related macular degeneration diagnostics
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016008975A1 (en) 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
EP3233115B1 (en) * 2014-12-19 2021-02-17 Children's Hospital Medical Center Methods and compositions related to transplant-associated thrombotic microangiopathy
JP2018512880A (ja) 2015-04-24 2018-05-24 アジーナ バイオサイエンス, インコーポレイテッド 少量の対立遺伝子および多型の同定ならびに定量のためのマルチプレックス法
CN104878105B (zh) * 2015-06-02 2017-10-31 北京医院 一种预测雷珠单抗治疗年龄相关性黄斑变性疗效的试剂
CN104894261B (zh) * 2015-06-02 2020-02-14 北京医院 一种预测雷珠单抗治疗年龄相关性黄斑变性疗效的试剂盒
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
HK1257422A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 抗-因子d抗体变体缀合物及其用途
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017148904A1 (en) * 2016-02-29 2017-09-08 Franz Grus Predictive markers useful in the treatment of wet age-related macular degeneration
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
EP4257191A3 (en) 2016-06-21 2023-11-22 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113373236B (zh) * 2021-02-19 2021-12-31 中国科学院北京基因组研究所(国家生物信息中心) 一种获得中国人群个体年龄的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
AU9381598A (en) 1997-09-10 1999-03-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of amplifying dna and rna mismatch cleavage products
AU2005314461B2 (en) * 2004-11-18 2012-02-02 The Rockefeller University Methods and compositions for treating ocular disorders
WO2008103299A2 (en) * 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration

Similar Documents

Publication Publication Date Title
RU2015101034A (ru) Генетические полиморфизмы при возрастной дегенерации желтого пятна
US20220206001A1 (en) Methods and systems for detecting coronavirus
EP4142784A2 (en) Variant nucleic acid libraries for coronavirus
JP2009541204A5 (enExample)
JP2020526478A5 (enExample)
JP2011528561A5 (enExample)
JP2007510664A5 (enExample)
JP2015212281A5 (enExample)
RU2009120052A (ru) Композиции и способы связывания сфингозин-1-фосфата
JP2016516400A5 (enExample)
RU2015126533A (ru) Анти-cd47 антитела и способы их применения
CA2938731A1 (en) Methods of treating alzheimer's disease
JP2021501744A5 (enExample)
CN106536754A (zh) 用il‑13拮抗剂选择性治疗哮喘的方法
JP2010533495A5 (enExample)
NZ602621A (en) Antibodies against csf-1r
JP2009539348A5 (enExample)
JP2022525377A5 (enExample)
JP2020537520A5 (enExample)
RU2013153592A (ru) Анти-mif антитела
JP2017507130A5 (enExample)
JP2011527899A5 (enExample)
JP2018518151A5 (enExample)
JP2019534892A5 (enExample)
EP2635704A1 (en) Predicting progression to advanced age-related macular degeneration using a polygenic score